Annual report pursuant to Section 13 and 15(d)

Business and Organization (Details)

v3.6.0.2
Business and Organization (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Aug. 31, 2016
USD ($)
$ / shares
shares
Aug. 31, 2015
USD ($)
$ / shares
shares
May 31, 2015
USD ($)
$ / shares
shares
Dec. 31, 2016
person
Transition Therapeutics, Inc.        
Business Acquisition [Line Items]        
Total purchase price $ 58,500      
Bio-Reference Laboratories, Inc.        
Business Acquisition [Line Items]        
Total purchase price   $ 950,148    
Common stock value   $ 2,259    
EirGen Pharma Limited        
Business Acquisition [Line Items]        
Total purchase price     $ 133,800  
Common stock value     33,600  
Cash payment to acquire business     $ 100,200  
Common Stock        
Business Acquisition [Line Items]        
Stock price (in dollars per share) | $ / shares $ 9.10 $ 12.38 $ 13.88  
Common Stock | Transition Therapeutics, Inc.        
Business Acquisition [Line Items]        
Common stock received, in shares (in shares) | shares 6,431,899      
Common Stock | Bio-Reference Laboratories, Inc.        
Business Acquisition [Line Items]        
Common stock received, in shares (in shares) | shares   76,566,147    
Acquired entity share price (in usd per share) | $ / shares   $ 34.05    
Common Stock | EirGen Pharma Limited        
Business Acquisition [Line Items]        
Common stock received, in shares (in shares) | shares     2,420,487  
Diagnostics        
Business Acquisition [Line Items]        
Sales force, persons (in persons) | person       400